arrow_back Back Filing freshness 10-Q FY 2026 SEC EDGAR

Agentix Corp.

AGTX
— Price unavailable
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
14 Visible periods
25 Metrics
Peer-ranked Benchmarks
Price Chart
49
Health
Weak
Neutral
auto_awesome

Analytical Summary

Agentix Corp. shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap —
Dividend Yield —
Revenue Growth None
Op. Margin —
ROIC 12.4% ↘
FCF / Share None
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity —
info Valuation on last close.

14-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.24K
— 0.0% —
Net Income Profit after all expenses
$-485.64K
↑ +14.4% —
Long-Term Debt Long-term obligations
$85.00K
↑ +70.0% —

Health Breakdown

Returns ↓
69
Financial Health ↑
34
Cash Quality ↑
27

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 14 years · 54 quarters